EBOS increases its shareholding in Transmedic to 90%

19 December 2023

NZX/ASX Code: EBO

EBOS increases its shareholding in Transmedic to 90%


EBOS Group Limited (EBOS) is pleased to announce that it has (via one of its wholly owned
subsidiaries) increased its shareholding in Transmedic Pte Ltd (Transmedic) from 51% to 90%.

Transmedic is one of the largest independent medical device distributors in Southeast Asia with a
presence in seven countries, being Singapore, Indonesia, Malaysia, Philippines, Thailand, Hong Kong
and Vietnam. Transmedic has long term relationships with global medical device manufacturers,
representing their products in hospitals and other clinical settings across several therapeutic
channels, including spine, orthopaedics, cardiology, ophthalmology and radiation therapy.

EBOS acquired its original 51% interest in Transmedic as part of the LifeHealthcare acquisition, which
completed in May 2022. The purchase price for the additional 39% shareholding in Transmedic is
approximately SGD119 million (AUD135 million
1
). The purchase price was funded from existing debt
facilities and the transaction is expected to be immediately marginally EPS accretive.

Transmedic major shareholder and Chairman, Mr TS Lee, has agreed to retain a 10% shareholding in
Transmedic and remain Chairman for a further approximately two years. An option arrangement has
been entered into that will facilitate EBOS moving to 100% ownership at the conclusion of this
period.

In commenting, EBOS Chief Executive Officer John Cullity said “Transmedic has performed very well
under EBOS’ ownership. This transaction reflects our confidence in the business and is consistent
with our strategy to explore further growth opportunities in Southeast Asia. We are delighted that TS
Lee will remain our partner in Transmedic and that EBOS will continue to benefit from his extensive
knowledge of the business and the region.”


For further information please contact:
Martin Krauskopf
Executive General Manager, Strategy and Mergers & Acquisitions
+61 3 9918 5555
Martin.Krauskopf@ebosgroup.com

Authorised for lodgement with NZX and ASX by Janelle Cain, General Counsel, EBOS Group Limited.


About EBOS Group
EBOS Group Limited NZBN 9429031998840 (NZX/ASX Code: EBO) is the largest and most diversified
Australasian marketer, wholesaler and distributor of healthcare, medical and pharmaceutical
products. It is also a leading Australasian animal care brand owner, product marketer and distributor.


1
Based on an SGD:AUD exchange rate of 0.8816